Rectify Pharma
PrivateLast Round
Strategic
Dec 22, 2025
Total Funding Raised
$100M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Rectify Pharma is a biotechnology company developing disease-modifying precision therapies through positive functional modulators that restore ABC transporter function to treat genetic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rectify Pharma Comparables
Compare Rectify Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Maze Therapeutics | 73% | |
| Novartis | 70% | |
| Judo Bio | 61% |
Rectify Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Dec 22, 2025 | ||||
| Series A | Oct 14, 2021 |
Key People
Founding team and executive leadership
Rectify Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boehringer Ingelheim | Strategic |
| Omega Funds | Series A |
| Dean Capital Investments Management | Series A |
| Forbion | Series A |
| Atlas Venture | Series A |
| Longwood Fund | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 23, 2026
Grew 16% QoQ, from 19 to 22 employees.
- Jul 26, 2026
Grew 17% QoQ, from 18 to 21 employees.
Recent news
Latest coverage and updates
- is_developingAug 27, 2026
Rectify Pharma is developing Positive Functional Modulators on Aug 27th '26.
- attends_eventAug 27, 2026
Rectify Pharma attended event American Chemical Society Fall 2026 Meeting on Aug 22nd '26.
Rectify Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Rectify Pharma's valuation, stock price, and market status.
Is Rectify Pharma a public or private company?
Rectify Pharma is a private company.
What is the current stock price of Rectify Pharma?
Rectify Pharma is a private company, so its shares have no public market price. Caplight tracks Rectify Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Rectify Pharma worth (valuation)?
Valuation information for Rectify Pharma is not publicly available.
Can I buy Rectify Pharma stock?
Rectify Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Rectify Pharma's last funding round?
Rectify Pharma's most recent funding round was Strategic on December 22, 2025.
Who are the main investors in Rectify Pharma?
Key investors in Rectify Pharma include Omega Funds, Forbion, Atlas Venture, Longwood Fund.
Will Rectify Pharma IPO soon?
No public IPO plans have been announced for Rectify Pharma.
How can I track Rectify Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Rectify Pharma's shares on secondary markets.